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Abstract
Opioid prescription related overdose deaths have increased substantially with evidence
demonstrating only modest short-term benefits in chronic pain and thus represents the need to
identify alternative treatments to opioids. A needs assessment performed for a federally
qualified community health center revealed patients presently taking non-opioid pharmacologic
agents in the treatment of chronic non-cancer pain (CNCP) needed additional education in
managing multiple non-opioid medications. A targeted approach at improving patient
experience and population health supporting the quadruple aim was undertaken with this
project.
Purpose
The purpose of this quality improvement project consisted of performing medication
management visits for 28 referred patients with CNCP encompassing a focused review of all
non-opioid pharmacologic agents being taken with tailored patient education completed. This
alternatives to opioids region of need was targeted in support of maximizing the use of nonopioid pharmacologic agents in the first line treatment of CNCP.
Interventions and Setting
Over the course of four weeks in a federally qualified community health center, twentyfive patients had completed medication management visits via telehealth, initially referred by
their healthcare provider as patients in need of further non-opioid chronic pain medication
management education. Each visit consisted of an introduction, visit goals overview, consent to
proceed, focused review of all non-opioid pharmacologic agents taken for CNCP, tailored
individualized education, and a post visit survey.
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Evaluation
A high incidence of polypharmacy was noted with most patients taking multiple nonopioid pharmacologic agents for CNCP with a low incidence of patients taking these
medications as prescribed. The outcome measurement comprises patient knowledge based on
the survey questions and a majority of the patients self-scored as agreed or strongly agreed
following the visits concerning awareness of medication indicated for pain, confidence on how
to take the prescribed medication and side effect profile familiarity.
Discussion
Improvement opportunities continue to exist in supporting chronic pain patients,
particularly in the first line treatment setting to maximize therapies and response. This project
has great potential for sustainability and improvement in patient knowledge surrounding
medication administration to enhance the first line non-opioid pharmacologic treatment of CNCP
in all outpatient settings.
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Problem Identification and Evidence Review
As a nation, opioid prescriptions for chronic pain have increased substantially with
approximately 35% of all opioid overdose deaths in 2017 attributed to prescription medications
(AHRQ, 2019). Opioid evidence shows only modest short-term benefits for chronic pain, thus,
there is a need to identify alternative treatments to opioids (AHRQ, 2019). Centers for Disease
Control and Prevention (CDC) 2016 guidelines for prescribing opioids for chronic pain
recommends nonopioid therapy as preferred treatment for chronic pain (Dowell, Haegerich, &
Chou, 2016). Quality improvement initiatives are needed in the management of chronic pain,
opioid prescriptions, and alternative modalities supporting the Connecticut opioid education
initiative and the 2011 Institute of Medicine (IOM) report.
Description of Local Problem
Patients with chronic pain may not be aware of the various options for treatment and lack
of knowledge of the alternative pain treatments is directly inhibiting the ability to participate in a
shared decision-making process. There are limited methods to facilitate increased awareness for
prescribing care practitioners at the project site, a federally qualified community health center, of
the availability of non-opioid pharmacologic agents in treating chronic pain. A further needs
assessment revealed patients presently taking non-opioid pharmacologic agents in the treatment
of chronic non-cancer pain needed additional education in managing multiple non-opioid
medications. Targeting this area of need for improvement, can result in increasing patient
knowledge in managing current non-opioid medications to maximize the duration of first-line
agents in the treatment of chronic non-cancer pain.
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Organizational Priority
This project has the support of the sites Medical Director, Behavioral Health APRN, and
Primary Care APRN. In addition, this project is supported by the Alternative to Opioids for Pain
(ALTOP) grant and in partnership amongst Sacred Heart University Davis Henley College of
Nursing (SHU DHCON) and the practice site, a federally qualified community health center, to
maximize the use of non-opioid pharmacologic agents in the first line treatment of chronic noncancer pain.
Focused Search Questions
In primary care patients with different etiologies for chronic pain (P) how do non-opioid
pharmacologic agents (I) compare to usual pharmacologic care (C) affect the treatment (O)?
External Evidence
A retrospective cohort study in patients with chronic non-cancer pain (CNCP) included
22,912 new episodes of prescribed therapy for both long-acting opioids and controlled
medications (Ray et al., 2016). Long-acting opioids compared with alternatives included
significantly increased risk of all-cause mortality, including deaths from overdose, with a modest
absolute risk difference (Ray et al., 2016). Narrative RCTs reviewed examined 271 trials and
concluded greater research is needed to determine effective mechanism-based treatments for
CNCP (Nicol, Hurley, & Benzon, 2017). The literature supports thorough provider consideration
of harms and benefits of treatment when counseling patients regarding therapies for chronic pain.
Internal Evidence
Cochrane review examined sixteen reviews offering quantitative data investigating opioid
agents and associated adverse events used in the treatment of CNCP (Els et al., 2017). Results
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included significantly increased risk of experiencing any adverse event (AE) with opioids
compared to placebo (risk ratio (RR) 1.42, 95% confidence interval (CI) 1.22 to 1.66) as well as
with opioids compared to a non‐opioid active pharmacological comparator, with a similar risk
ratio (RR 1.21, 95% CI 1.10 to 1.33) (Els et al., 2017). Additional systematic review of RCT data
in opioids for CNCP revealed potential opioid benefit, however, magnitude is likely to be small
(Busse et al., 2019). Long-term opioids prescribed to patients with chronic pain have limited
benefits and non-opioid pharmacologic alternatives should be considered (Tauben & Stacey,
2021).

Evidence Appraisal, Summary, and Recommendations
A total of 16 articles met the criteria for inclusion in this evidence review with mainly
evidence level two ratings. In order to select the article to include in the review, it had to evaluate
a non-opioid pharmacologic agent for a specific type of pain in the outpatient setting. Appendix
A displays the pertinent information from each of these reviews. Systematic reviews in the
Cochrane database (n=14) identified studies of long-term opioid use for chronic non-cancer pain
(CNCP) and this quality evidence demonstrated side effects can occur in patients with CNCP
who use opioid medicines for greater than two weeks. The evidence ranged in chronic pain
conditions treated with opioids, however, these conditions were also found to have efficacious
non-opioid therapies listed. Randomized control trials did not support opioid therapy for
treatment of moderate to severe chronic pain conditions of varying forms.
Based on this evidence review and synthesis, there is evidence supporting the CDC
guidelines in using non-opioid pharmacologic treatments in the first line setting for CNCP.
There are various effective opioid alternative pharmacologic therapies to treat common chronic
pain conditions. Providers should council the patient and strongly consider, an opioid alternative
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pharmacologic agent in the treatment of CNCP shown to be effective for decreasing pain,
potential drug related toxicity, improving physical function, and/or quality of life compared to
the opioid counterpart.

Phase 2: Project Planning
Project Goals
1. Identify non-opioid pharmacologic treatments for chronic non-cancer pain management.
2. Identify 25 to 30 patients with chronic non-cancer pain currently taking non-opioid
pharmacologic agents for chronic non-cancer pain management.
3. Schedule and perform a medication management visit, in person or via telehealth with
each identified patient which will include a focused review of all non-opioid
pharmacologic agents utilized by the patient for chronic non-cancer pain.
a. Education will be tailored to individual patient needs.
b. Educational information handouts provided post visit, reinforcing individual
patient medication touch points utilizing literacy-level appropriate materials.
c. A post visit survey will be completed with each patient.
4. Disseminate information on completed medication management visits in patients
presently using non-opioid pharmacologic treatments for chronic non-cancer pain to
SWCHC project partners.
Framework
The 4C approach to quality improvement will guide this project. The steps in the 4C model
are:
 Center: identify the issue, identify/set goals
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 Collaborative Groups: assemble a team to work on the project that includes members
that will be impacted by the change
 Change: implement the change using implementation strategies
 Celebration: celebrate and acknowledge improvement efforts (McGonigal, 2017)
Context
The practice site is a federally qualified health center that provides medical, dental,
behavioral health services, health education, disease prevention programs, community outreach,
homeless health program, and registration services to individuals and families in the Greater
Bridgeport area. The practice site has a total of seven primary care clinics located throughout the
city of Bridgeport and is a covid-19 testing center (SWCHC, 2022).
Key stakeholders
Key stakeholders include the practice sites prescribing providers of patients referred for
medication management. The project team includes lead program staff such as the chief medical
officer, QI director, behavioral health provider, primary care provider, and project manager for
the Alternatives to Opioids for Pain (ALTOP) Grant. Dorothy Esposito, DNP MSN/ed, APRN,
FNP-BC is the academic partner, DNP project faculty advisor, and evidence-based practice
expert.
Practice change/Intervention
The proposed intervention will begin with the identification and referral of 25 to 30
patients with chronic non-cancer pain presently taking non-opioid pharmacologic agents for
chronic non-cancer pain management. The patients will be identified by the referring provider as
patients in need of further non-opioid chronic pain medication management education.
Medication management visits will be performed either in clinic or via telehealth. The
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implementation process for each medication management visit will begin with an introduction,
visit goals overview, and consent to proceed with the visit. The DNP student will perform the
medication management visit inclusive of the post visit survey (Appendix B), a focused review
of all non-opioid pharmacologic agents utilized by the patient for chronic non-cancer pain and
offer individualized patient education with appropriate literacy level handouts provided
reinforcing individual patient medication touch points following the visit. Written and verbal
summaries on individual medication management visits will be afforded to the referring
provider. Real-time collaboration with the referring provider will also be utilized as appropriate.
The target goal will be for 90% of all patients referred to have completed medication
management visits. The DNP student will review the ongoing and completed results of the
medication management visits with the ALTOP team at the monthly meetings as well as provider
emails and onsite communications. A summary of lessons learned will be developed by the DNP
student and used to inform any future changes.
Possible Barriers to Implementation
The most common barriers to implementation may certainly include a lack of time for
busy primary care providers in a community health center to consider patient referral and
resistance to change due to culture or practice. Barriers to sustainability may include again a lack
of time for provider referral, provider time constraints for ongoing dialogue with the DNP
student, and patient scheduling limitations due to the pandemic and staffing shortages. Strategies
to address these barriers include limiting the provider referral base to two providers with an
ample chronic pain patient population base and simplifying the referral and communication
feedback loops. These support mechanisms should encourage the two providers to utilize the
DNP project medication management visits to educate their referred patients on the use of non-
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opioid pharmacologic agents in the treatment of chronic non cancer pain and maximize the first
line of treatment.
Sustainment
Ongoing project change can be sustained by communicating updated data on medication
management visits aimed at maximizing the patients use of non-opioid pharmacologic agents in
the treatment of their non-cancer chronic pain. Revisions to the project will be made based off
stakeholder responses to enhance sustainability. In addition, celebrating provider success will
take place on a regular basis throughout the project.
There is an opportunity for the intervention developing into a billable service for the
practice site. Evolving this into a billable service could support the sustainment of this type of
intervention and care needed in maximizing the duration of first line non-opioid pharmacologic
treatment of chronic non cancer pain patient population. Services would either be administered
via the qualified provider or directly supervised by the referring provider, and this would remain
a sustainability goal for the practice site post project completion.
Dissemination Plan

Initial project dissemination includes monthly updates concerning project progress to the
ALTOP team. Considering the development of an evidence-based practice (EBP) poster will
provide a professional announcement of evidence-based findings with visual data and tables of
the most fundamental aspects of this project. A poster presentation is a highly effective method
for communicating and internally disseminating the project’s important findings.
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Timeline
Nov-Dec 2020
•

Complete project proposal draft

Jan-April 2021
o Complete official DNP project proposal and present to practice site stakeholders
o January-April 2021 make revisions to project proposal as needed
May-Aug 2021
o Identify & obtain the required review and approval needed for implementation
Sep-Dec 2021
o Prepare project implementation
o Track any deviations from project plan and make changes if needed
Sep-Mar 2021/22
o Complete medication management visits for referred patients
April 2022
o Present final DNP project
o Submit final DNP project
o Submit executive summary
Resources
Anticipated resources for this project include:
1. People:
a. Patients, chief medical officer, quality improvement director, project manager
for the ALTOP Grant at the practice site, primary care providers in internal
medicine, and behavioral health professional.
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2. Capital:
a. Salaries for doing the work if not done as part of job may be required
3. Material:
a. Educational materials related to the project
b. Mailing materials inclusive of stamps, envelopes, & paper
c. Zoom account or alternate virtual meeting platform required
Ethical Merit
This project has been reviewed by the ALTOP grant team and does not require
Institutional Review Board approval as deemed a quality improvement project (see Appendix E).
Utilizing the differentiating quality improvement and research activities tool answers to
questions 1-10 are marked yes (see Appendix E). For questions 11-14 the answers are marked no
indicating that this project meets criteria for a quality improvement project, does not qualify as
human subjects ’research, and does not have to go through the Institutional Review Board at
Sacred Heart University (see Appendix E).

Project Implementation
The project was carried out using the previously selected 4C model and the project began
with the primary healthcare provider’s identification and referral of patients with chronic noncancer pain presently taking non-opioid pharmacologic agents for chronic non-cancer pain
management. Over the course of four weeks, thirty-eight patients were identified and referred by
the earlier identified two providers at the practice site. All thirty-eight patients were identified by
the referring provider as patients in need of further non-opioid chronic pain medication
management education. Each patient was contacted for medication management visits via
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telehealth. Patients were left messages if not initially reached by phone and follow-up phone
calls were also performed at varying times of day.
The implementation process for each medication management visit began with an
introduction, visit goals overview, and consent to proceed with the visit. A total of twenty-eight
patients were reached via telephone and agreed to continue with the medication management
visit. Each patient had a completed medication management visit performed by the DNP student.
Medication management visits incorporated a focused review of all non-opioid pharmacologic
agents utilized by the patient for chronic non-cancer pain, tailored individualized medication
education as needed, a post visit survey (Appendix D), and an offer for individualized patient
education with appropriate literacy level handouts reinforcing individual patient medication
touch points following the visit. Written and verbal summaries on individual medication
management visits were afforded to the referring provider following the completion of the
medication management visits. Real-time collaboration with the referring provider was also
utilized when needed and as appropriate.
Project Plan Deviations
The initial project implementation was targeted for the fall of 2021. Due to extensive
project revisions, the project implementation was delayed until February 2022. The initial intent
of the project was provider education focused. Feedback elicited combined with the practice
site’s provider workflow volume changes over the course of the project’s development
demonstrated a greater area of need for education concerning the directed patient population.
Necessary project revisions aimed at focusing the education intervention on the detailed patient
population caused a deviation and delay.
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Initial implementation barriers included EMR access delays due to new practice site
system security training, student re-approval for remote work delays, and several calls with
practice site informational technology support over the course of two weeks to reset expired
passwords.
Further patient scheduling barriers involved difficulty reaching patients via telephone with the
inability to leave messages, whether for a full voicemail box or no voicemail box set up, and
unreturned call backs. This represented a deviation from the project plan as the completed
medication management visit goal was set for 90% while only less than that of patients were
reached.
Evaluation
A target goal was established for 90% of all patients referred to have completed
medication management visits. Of the thirty-eight patients referred, a total of twenty-eight had
completed medication management visits, representing 74% of the referred population as
reflected in Table 1.
Table 1.
Patients Referred for Medication Management Visits n=38

VISITS COMPLETED
Visits completed

Visits not completed

26%

74%

17
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Process Measures. The process measurement included tracking the number of
medication management visits performed focusing on non-opioid pharmacologic agents in the
treatment of chronic pain. Descriptive statistics collected from the EHR inclusive of
demographics, indicated diagnosis for non-opioid medications, number and variety of non-opioid
medications, and therapeutic medication classes. Post survey responses were collected and
grouped as appropriate for reflection in the qualitative findings. Table 2, 3, and 4 display
available data.
Table 2.
Patient Characteristics
Characteristics
Age > 18
Gender
Male
Female

Patient completed Visits
(n=28)
28
8
20

Race
Asian
Black / AA
White
Declined

1
9
17
1

Ethnicity
Not Hispanic or Latino
Hispanic or Latino
Declined to specify/unknown

17
9
2

Chronic Pain Location
Head
Neck
Back/lower back
Hands/Feet
Abdominal
Knee
Whole Body
Other
Combination > 1 site

2
2
11
4
1
3
3
2
28
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Table 3.
Indicated Diagnosis for non-opioid prescription

Referral diagnosis (n=28)
16
14
12
10
8
6
4
2

0

19

Table 4.
Prescription Classes and Associated Details

Prescription Classes and Associated Details
16
14
12
10
8
6
4
2
0

Currently taking

Dosing as prescribed

Determined Effective

Side Effects

Outcome Measurements. The outcome measurement comprises patient knowledge
based on the survey questions surrounding awareness of medication indicated for pain,
confidence on how to take the prescribed medication and side effect profile familiarity. Data
collection includes post visit survey. See Table 5.
Table 5.
Patient knowledge assessments
Survey Questions
Post Visit n=28
1
0

2
1

3
0

4
14

5
13

2. I am confident on how to take
my medication(s)s for pain.

0

0

0

17

11

3. I am familiar with the side
effects of the medication(s) I
take for pain.

0

3

0

16

9

1. I know which of my
medication(s) to take for
different types of pain.

Key: 1= Strongly Disagree, 2= Disagree, 3= Sometimes, 4= Agree, 5= Strongly Agree

Return on Investment. The return on investment (ROI) is utilized to evaluate the
financial impact of the project and is generated from the estimated financial value of the practice
change subtracted from the estimated actual project costs. The total profit the project is estimated
to generate is then divided by the project costs. Total project costs were estimated at $800.00
including provider time for 30-minute visits based on an average annual salary, printing
materials, and mailing supplies cost for a total of twenty-five completed patients. The anticipated
financial value generated via a billable and service for a sample size of twenty-five patients
represents $1950.00. Medicare 2022 reimbursement rates utilizing medication management CPT
codes estimated the expected financial return. An estimated ROI of 1.45% is observed.
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Dissemination
Implications of Project Results to Organization and Practice Community
Initial project dissemination included monthly updates concerning project progress to the
ALTOP team and final project presentation on April 12, 2022. Project results and practice
community implications were presented to the organization. Additional evidence-based practice
(EBP) poster dissemination involved both the practice site organization and DNP program.
Executive Summary. The executive summary was developed as a highly summarized
description of the project. As detailed in Appendix F, the executive summary includes the
projects’ purpose, methods, results, conclusions, and recommendations for sustainability.
Electronic Poster. The development of an evidence-based practice (EBP) poster was
completed and provided within the DNP program as a professional announcement of evidencebased findings with visual data and tables of the most fundamental aspects of this project as
demonstrated in Appendix G. A poster presentation is a highly effective method for
communicating and internally disseminating the project’s important findings.
Practice Organization Presentation. The final project dissemination concluded in an
ALTOP meeting project presentation with key stakeholders in attendance from the practice site,
and DNP program professors, project, and clinical advisors. Additional DNP program peers were
in attendance as well.

Key Lessons Learned
Enhanced patient referrals resulted in limiting the number of providers through project
engagement and enhanced feedback loop communication. Ease of referral process and ample
patient population also contributed to the robust patient referrals. Barriers in contacting patients
via telehealth could have been improved upon by targeting an onsite day for patient visits.
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Sustainability Plan
Improvement opportunities continue to exist in supporting chronic pain patients,
particularly in the first line treatment setting to maximize therapies and response. This project
has great potential for sustainability with practice site leadership support, opportunity for a
billable service, and improvement in patient knowledge surrounding medication administration.
Several factors in place contributing to the success of this project include the robust chronic pain
patient population, dedicated providers, and the organizational support for alternatives to opioids
working under the ALTOP grant. The organizational and faculty partnerships strengthened
during this project enhance the potential for project sustainability.
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Appendix A
Description of Evidence Search
A search of the subsequent databases was conducted; CINAHL, MEDLINE, and the
Cochrane Database of Systematic Reviews. The key words searched included; non-opioid
pharmacologic agents, providers, prescribers, clinicians, health care professionals (HCPs), nonopioid medications, chronic pain, prescribing, non-opioid analgesics, and opioid alternative
medications. Limits and filters added for all searches pertaining to the aforementioned search
terms included, English language, adults (age 18 and over) and published between 2010 – 2020.
Inclusion criteria for article selection pertained to non-opioid pharmacologic agents, chronic
pain, and may have or have not included prescribing practices. Tables 1 through 3 display the
database, search terms and results of search.
PICO question: In primary care patients with different etiologies for chronic pain (P) how does
non-opioid pharmacologic agents (I) compare to usual pharmacologic care (C) affect the
treatment (O)?
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Table A1.
CINAHL Complete Search Terms and Search Results
Search Terms

Number
of hits

Number
of title &
abstract
reviewed

Number
of fulltext
articles
reviewed

Non-opioid pharmacologic agents

882

Providers & Non-opioid medications

3

3

Prescribers & Non-opioid medications

1

1

Physicians or doctors or clinicians or HCPs &
non-opioid medications

3

3

1

Non-opioid medications

64

Non-opioid medications & chronic pain

22

11

3

Prescribing non-opioid medications & chronic
pain

656

23

Prescribing practices & non-opioid
medications

1

Non-opioid analgesics & chronic pain

56

Chronic pain & opioid alternative medications

7

Duplicates

Number of
articles
selected for
this review
without
duplicates

1

11

1

1

2

2
2
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Table A2. Medline Search Terms and Search Results
Search Terms

Number
of hits

Number
of title &
abstract
reviewed

Non-opioid pharmacologic agents

1907

Providers & Non-opioid medications

6

Prescribers & Non-opioid medications

2

1

Physicians or doctors or clinicians or HCPs &
non-opioid medications

11

3

Non-opioid medications

52

Non-opioid medications & chronic pain

17

Prescribing non-opioid medications & chronic
pain

325

Prescribing practices & non-opioid
medications

2

Non-opioid analgesics & chronic pain

117

Chronic pain & opioid alternative medications

6

8

Number
of fulltext
articles
reviewed

Duplicates

Number of
articles
selected for
this review
without
duplicates

12
13

25

123

1

4
4

1
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Table A3.
Cochrane Database of Systematic Reviews Search Terms and Search Results
Search Terms

Number
of hits

Number
of title &
abstract
reviewed

Number
of fulltext
articles
reviewed

Duplicates

Non-opioid pharmacologic agents

39

5

Number of
articles
selected for
this review
without
duplicates
3

2

2

Providers & Non-opioid medications
Prescribers & Non-opioid medications
Physicians or doctors or clinicians or HCPs &
non-opioid medications
Non-opioid medications

2

Non-opioid medications & chronic pain
Prescribing non-opioid medications & chronic
pain

1

Prescribing practices & non-opioid
medications
Non-opioid analgesics & chronic pain

2

Chronic pain & opioid alternative medications

6

Appendix B
Search Question in PICO format: In primary care patients with different etiologies for chronic pain (P) how does non-opioid
pharmacologic agents (I) compare to usual pharmacologic care (C) affect the treatment (O)?
Article
number

First
author
year

Neuropathic Pain
1
Arezzo
(2008)

Purpose

Evidence
type, level of
evidence

Sample,
setting

Major Variables
Study and their
Definitions

How major variables
were measured

Findings that help
answer question

Results worth
to
practice/project,
quality of
evidence

Efficacy
evaluation in
DPNassociated
neuropathic
pain

Randomized,
doubleblind,
placebo
controlled
trial
II

167,
13 week
parallel-group
trial across 23
outpatient
centers in U.S

Endpoint mean
pain score
(MPS),

11-point scale
MPS

•

-significant
pain
improvement
evident @ 1
week &
sustained
weekly
timepoints

•

-pre-existing
painful DPN
>/=3 months

2

Devi
(2012)

Reduction in
neuropathic
pain severity

Prospective,
randomized,
open label,
comparative
study
II

152,
outpatients
Dept. of
Endocrinology
& Neurology,
St. Johns
Medical
College
Hospital
Bengaluru

pain severity
(3 tx groups)

11-point VAS (0=no
pain – 10=worst
possible pain)
-recording ADRs

-safety of study
medication

•

Pregabalin
600mg/d
(300mg BID)
effectively
reduced pain
& well
tolerated
pregabalin tx
pts lower
MPS than
controls
(mean
difference 1.28; p<.001)
Head to head
comparison
for
Gabapentin,
Pregabalin,
Duloxetine w/
all 3
demonstrating
significant
reduction in
pain

-this trial
important
addition to
pregabalin &
neuropathic
pain literature
-all 3 treatment
groups
significant
reduction in
VAS for pain
across 12
weeks (P<0.05)
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Article
number

First
author
year

Purpose

Evidence
type, level of
evidence

Sample,
setting

Major Variables
Study and their
Definitions

How major variables
were measured

Findings that help
answer question

3

Kelle
(2012)

Compare
effectiveness
of
gabapentin
& pregabalin
in
neuropathic
pain due to
peripheral
nerve injury

Randomized,
II

30, Military
veterans w/
neuropathic
pain r/t
peripheral
nerve injury
-2 groups
(Gabapentin
vs Pregabalin)
-tertiary care
hospital

Pain at baseline,
1 week, 1
month, 3 months

11-point VAS (0=no
pain – 10=worst
possible pain)

•

mean
reduction in
VAS pain
statistically
significant (P
< 0.05) in
both groups

4

Backonja
(2008)

percentage
change in
NPRS score
from
baseline to
weeks two to
eight.

Randomized,
II

402, Patient
ages 18–90,
had had
postherpetic
neuralgia for
at least 6
months, & had
average
baseline
numeric pain
rating scale
(NPRS) score
of 3 to 9.

numeric pain
rating scale
(NPRS) score

#1 60 min application
of 8% capsaicin or
low concentration
capsaicin control
patch.

•

pts assigned
to 8%
capsaicin had
significantly >
pain reduction
in pain during
weeks 2 to 8
than those w/
control patch.
Mean changes
in NPRS
score -29.6%
vs -19.9%
(difference 9.7%, 95% CI
-15.47 to 3.95;
p=0.001)

150 subjects,
in 3 outpatient
research
centers in the

Brief pain
survey (BPI)
average pain

Fibromyalgia
5

Arnold
(2007)

Compare
gabapentin
vs placebo
for efficacy

Randomized,
II

% change in NPRS
score from baseline to
wks 2 to 8
•

Response to treatment
was defined as a
reduction of
>or=30% in this

Gabapentintreated patients
displayed a
significantly

Results worth
to
practice/project,
quality of
evidence
- significant
reduction in
VAS for pain
across all
timepoints

>pain reduction
in patients
using 8%
capsaicin for
post herpetic
neuralgia

≥30% pain
reduction (BPI)
in Gabapentin
treated patients
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Article
number

First
author
year

Purpose

Evidence
type, level of
evidence

& safety in
treating pain
associated
with
fibromyalgia

6

Arnold,
2008

assess the
efficacy and
safety of
pregabalin
monotherapy
in patients
with
fibromyalgia

Randomized
doubleblind, multidose,
placebocontrolled
II
(Industry)

32

Sample,
setting

Major Variables
Study and their
Definitions

How major variables
were measured

Findings that help
answer question

U.S., ages >18
& met ACR
criteria for
fibromyalgia

severity score
(range 0-10)

score. The primary
analysis of efficacy
for continuous
variables was a
longitudinal analysis
of the intent-to-treat
sample, with
treatment-by-time
interaction as the
measure of effect.

745,
84 outpatient
research
centers across
U.S.

- Brief pain
survey (BPI)
average pain
severity score
(range 0-10)

-Pregabalin
600mg/450mg/300mg
per day
Vs
Placebo
-BPI-S Avg pain
scale 0-10 (NRS), 14
weeks

greater
improvement in
the BPI average
pain severity score
(P=0.015;
estimated
difference
between groups at
week 12=-0.92
[95% confidence
interval -1.75, 0.71])
- All three
monotherapy
dosing groups
demonstrated
statistically
significant
improvement
compared w/
placebo treated pts

>18y/o, FM
class met,
baseline pain
score of at
least 40mm on
the 100mm
visual analog
scale (VAS)

-wkly mean pain
scores in all 3
pregabalin tx
groups
significantly
separated from
placebo as early as
week 1, &
significant
improvement was
sustained until
EOT period (week
14), with the

Results worth
to
practice/project,
quality of
evidence

≥30% pain
reduction (BPI)
in all
Pregabalin
treated patients
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Article
number

First
author
year

Purpose

Evidence
type, level of
evidence

Sample,
setting

Major Variables
Study and their
Definitions

33
How major variables
were measured

Findings that help
answer question

Results worth
to
practice/project,
quality of
evidence

exception of 300
mg/d at week 11.
7

Branco,
2011

Investigate
long term
efficacy &
safety of
milnacipran
in tx of FM

Randomized,
doubleblind,
extension
study
II
(Industry)

270,
70 outpatient
centers in 11
European
countries
Pts post 3
month lead in
study (double
blind
Milnacipran
tx, placebo
controlled)
18-71 y/o, FM
dx per ACR
criteria

8

Chappell,
2008

Assess
efficacy of
duloxetine
compared
with placebo
in FM
during 6
month tx
phase

Phase-III
randomized,
doubleblind,
placebocontrolled,
parallelgroup
II

307,
36 outpatient /
private
practices centers in
Germany,
Spain,
Sweden, UK,
U.S.

(Industry)

>18 y/o with
FM per ACR
criteria

-Weekly recall VAS
& PGIC

- Long term
extension study
shows the beneficial
effect of milnacipran
in FM at the 3
dosages tested and
the maintenance of
this effect over a 1year period. This
efficacy was
observed for the
pain

≥30% pain
reduction
(improvement in
weekly-recall
pain VAS score
& improved
PGIC) in all 3
treatment groups

- Brief pain
survey (BPI)
average pain
severity score
(range 0-10)

-BPI, if pt did not
have >50% reduction
at week 13, then
blindly escalated to
higher dose (120mg)

≥30% pain
reduction in both
treatment groups

- Patient global
impression of
change (PGIC):
pt rates
impression of
overall pain, 7 pt
scale

-Pain reduction
measured by BPI
from baseline to
endpoint & PGIC at
endpoint

Compared with
placebo-treated, pts
tx w/ duloxetine had
significantly greater
AUC of pain relief
& experienced
greater
improvements in
BPI least pain score
and average
interference score.

- weekly recall
pain (pt.
reported avg
level of pain
over the
previous week)
based on 1-100
paper Visual
Analog Scale
(VAS)
- Patient global
impression of
change (PGIC):
pt rates
impression of
overall pain, 7 pt
scale

-BPI avg pain
severity from
baseline to
endpoint
(P=0.053)
-PGIC at
endpoint
(P=0.073)
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Article
number

First
author
year

Purpose

Evidence
type, level of
evidence

Sample,
setting

Major Variables
Study and their
Definitions

How major variables
were measured

Findings that help
answer question

Results worth
to
practice/project,
quality of
evidence

9

Mease,
2008

Evaluate
efficacy &
safety of
Pregabalin
for
symptomatic
pain relief
associated
w/ FM

Randomized,
doubleblind,
placebocontrolled.
II
(Industry)

748,
79 research
outpatient
sites in U.S

- Baseline pain
intensity, NRS
(0-10)

-pt daily pain rating
for previous 24 hrs

-pregabalin,

≥30% pain
reduction in all
three treatment
groups

Test
superiority
of naproxen
compared w/
placebo in
relieving
signs &
symptoms of
Hip OA
Evaluate
efficacy &
safety of
duloxetine in
chronic pain
tx of Knee
OA

Randomized,
doubleblind,
parallelgroup,
multicenter
study.
II

810,
105 outpatient
centers in U.S,
Canada, &
Europe

Management
of
symptomatic

Randomized,
doubleblind,

Osteoarthritis
10

11

12

Baerwald,
2010

Chappell,
2011

Reginster,
2017

Randomized,
doubleblind,
placebocontrolled
II
(Industry)

>18, met ACR
dx for FM

>40 y/o dx of
primary hip
OA, +hip pain
256,
21 Outpatient
clinical sites,
>40 y/o dx of
OA knee

405,
Outpatients,
international
sites

- Baseline
function/disability:
SF-36 physical
functioning
(0-100)

-Western
Ontario &
McMaster
Universities
Osteoarthritis
Index
(WOMAC) pain
& function
subscales
-baseline pain
intensity, BPI
average pain (0
to 10)
-Weekly 24hour average
pain (0 to 10)
-CGI-S (1 to 7)
Pain reduction,
change from
baseline

-“responders” =
>30% reduction in
mean pain score from
baseline to endpoint

statistically
significant
improvement in
endpoint mean pain
score and in PGIC
response compared
with placebo

-Pregabalin
monotherapy
provides
clinically
meaningful
benefit to patients
with FM

-WOMA pain score
-VAS

-well tolerated and
promising tx for
OA of hip,
efficacy
statistically greater
than placebo

>50%
improvement in
pain or function

-BPI 24 hr average
pain rating,
duloxetine doses
increased if <30%
pain reduction from
baseline at week 7

-pain reduction
significantly
higher in
duloxetine group
compared to
placebo based on
primary efficacy
analysis of BPI
average pain
Celecoxib
provided a
significantly
greater reduction

≥30% pain
reduction from
baseline to
endpoint

Baseline pain
intensity, target knee
pain (VAS) (0 to 100)

≥40% pain
reduction
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Article
number

13

14

15

First
author
year

Uchio,
2018

Barthel,
2009

Altman,
2015

Purpose

Evidence
type, level of
evidence

knee
osteoarthritis

placebo
controlled
II
(Industry)
Randomized,
doubleblind,
placebo
controlled
II
(Industry)

Examine the
efficacy &
safety of
duloxetine in
pts. w/ OA
knee pain

Assessing
the efficacy
& safety of
topical
diclofenac
sodium 1%
gel in mildmod
symptomatic
knee OA

Randomized,
doubleblind,
vehicle
controlled
II
(Industry)

Evaluating
efficacy &
safety of
low-dose
SoluMatrix
Meloxicam
in pts. w/
OA-related
pain

Randomized,
doubleblind,
vehicle
controlled
II
(Industry)

Sample,
setting

>50 y/o,
primary knee
OA
354,
47 outpatient
medical
centers in
Japan
40-<80 y/o,
met ACR
criteria knee
OA pain
492,
64 outpatient
centers in U.S.

Major Variables
Study and their
Definitions

How major variables
were measured

Findings that help
answer question

Results worth
to
practice/project,
quality of
evidence

in pain after 3 & 6
months

Change in BPI
severity scales

Baseline pain
intensity, BPI
severity average pain
(0 to 10)

Duloxetine
reduced knee knee
pain associated
with OA

≥30% pain
reduction

Pain reduction,
change from
baseline

Western Ontario &
McMaster
Universities
Osteoarthritis Index
(WOMAC) pain
subscale

Over a 3-month
treatment period,
topical tx w/ DSG
achieved clinically
significant
improvements of
pain in pts. w/
knee OA

Significant
decreases in
mean WOMAC
pain (P=0.01)

Meloxicam group
experienced
significant
improvement from
baseline in
measures of pain.

≥30% pain
reduction

>35 y/o w/ dx
of
osteoarthritis
in 1 or both
knees

Pain on
movement

403,
outpatient
setting

Mean change
from baseline in
WOMAC pain
subscale score at
week 12

>40 y/o,
confirmed hip
or knee OA

35

Visual analog scale
assessing pain on
movment (VAS) (0 to
100)
Western Ontario &
McMaster
Universities
Osteoarthritis Index
(WOMAC) pain
subscale
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Article
number

First
author
year

Purpose

Evidence
type, level of
evidence

Sample,
setting

Major Variables
Study and their
Definitions

36
How major variables
were measured

Findings that help
answer question

Results worth
to
practice/project,
quality of
evidence

Therapeutic option
to manage OA
related pain
Low Back Pain

16

Konno,
2016

Assess
efficacy &
safety of
duloxetine in
pts w/
chronic low
back pain

Randomized,
doubleblind,
placebo
controlled
II
(Industry)

458,
58 outpatient
centers in
Japan
20-<80 y/o,
LBP for at
least 6
months,
current
NSAID users

Improvement in
BPI average
pain score from
baseline

Baseline pain
intensity, BPI average
pain (0-10)

Significant
improvement in
pain from baseline
in the Duloxetine
group

≥30% pain
reduction
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Appendix C
Table C1.
Level of Evidence Synthesis Table
Article Number

1

2

3

Level I: Systematic review or metaanalysis
Level II: Randomized controlled trial
Level III: Controlled trial without
randomization
Level IV: Case-control or cohort
study
Level V: Systematic review of
qualitative or descriptive studies
Level VI: Qualitative or descriptive
study, CPG, Lit Review, QI or EBP
project
Level VII: Expert opinion

4

5

X

X

6

7

X

X

8

X
X

X

X
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Table C2.
Outcomes Synthesis Table
Article
Number
Opioid
prescriptions
Non-opioid
prescriptions
Pain
intensity
Physical
functioning
improvement

1

2

3

4

5

6

7

8



ND

+

NE

+

NE

+

NE


(96%)
NE

ND

+

NE

+

NE

NE

NE

+
+
(control)
NE
+

ND

NE

NE

NE

NE

NE

ND

NE

NE

Pain

improvement
w/ opioids

NE

NE

 short
duration
 long
duration

ND
ND
(nonopioid/
placebo)
NE
ND

Pain
NE
improvement
w/
nonopioids
Opioid r/t

AEs

NE

NE

ND



ND

NE

(opioid/
nonopioid
combo)
NE


NE


(1.90
>risk)



NE



NE
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Appendix D
The following is a script to be completed with the patient post telehealth visit for the
chronic pain medication management visit.

For each of the topics listed below, please check the box under the number that indicates your
level of knowledge both before and after completing the medication education visit:
1= Strongly Disagree
2= Disagree
3= Sometimes
4= Agree
5= Strongly Agree

How do you rate your knowledge about the following topics:

Knowledge AFTER the
Visit
1

Q1. I know which of my medications to take for different types of
pain.
Q2. I am confident on how to take my medications for pain.
Q3. I am familiar with the side effects of the medications I take for
pain.

2

3

4

5
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Appendix E
Table E1.
Differentiating Quality Improvement and Research Activities Tool
Question
1.

Yes
Is the project designed to bring about immediate improvement in patient X
care?

2.

Is the purpose of the project to bring new knowledge to daily practice?

X

3.

Is the project designed to sustain the improvement?

X

4.

No

Is the purpose to measure the effect of a process change on delivery of X
care?

5.

Are ﬁndings specific to this hospital/setting?

X

6.

Are all patients who participate in the project expected to benefit?

X

7.

Is the intervention at least as safe as routine care?

X

8.

Will all participants receive at least usual care?

X

9.

Do you intend to gather just enough data to learn and complete the cycle? X

10.

Do you intend to limit the time for data collection in order to accelerate X
the rate of improvement?

11.

Is the project intended to test a novel hypothesis or replicate one?

X

12.

Does the project involve withholding any usual care?

X

13.

Does the project involve testing interventions/practices that are not usual
or standard of care?

X

14.

Will any of the 18 identifiers according to the HIPAA Privacy Rule be
included?

X

Adapted from Foster, J. (2013). Differentiating quality improvement and research activities. Clinical
Nurse Specialist, 27(1), 10–3. https://doi.org/10.1097/NUR.0b013e3182776db5
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Appendix F
Executive Summary
Opioid prescription related overdose deaths have increased substantially with evidence
demonstrating only modest short-term benefits in chronic pain and thus represents the need to
identify alternative treatments to opioids (AHRQ, 2019). A needs assessment performed for a
federally qualified community health center revealed patients presently taking non-opioid
pharmacologic agents in the treatment of chronic non-cancer pain (CNCP) needed additional
education in managing multiple non-opioid medications. A targeted approach at improving
patient experience and population health supporting the quadruple aim was undertaken with this
project (Arnetz et al., 2020).
Purpose
The purpose of this quality improvement project consisted of performing medication
management visits for 25 referred patients with CNCP encompassing a focused review of all
non-opioid pharmacologic agents being taken with tailored patient education completed. This
alternatives to opioids region of need was targeted in support of maximizing the use of nonopioid pharmacologic agents in the first line treatment of CNCP.
Methods
Over the course of four weeks in a federally qualified community health center, twentyfive patients had completed medication management visits via telehealth, initially referred by
their healthcare provider as patients in need of further non-opioid chronic pain medication
management education. Each visit consisted of an introduction, visit goals overview, consent to
proceed, focused review of all non-opioid pharmacologic agents taken for CNCP, tailored
individualized education, and a post visit survey.
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Results
The outcome measurement comprises patient knowledge based on the survey questions
and a majority of the patients self-scored as agreed or strongly agreed following the visits
concerning awareness of medication indicated for pain, confidence on how to take the
prescribed medication and side effect profile familiarity.
Conclusions
A high incidence of polypharmacy was noted with most patients taking multiple nonopioid pharmacologic agents for CNCP. Even further problematic, there was a noted low
incidence of patients taking these medications as prescribed. The education provided during the
medication management visit positively impacted the patient’s awareness of taking the
medications as prescribed, confidence level of managing multiple non-opioid medications, and
familiarity with side effects of these medications.
Recommendations
Improvement opportunities continue to exist in supporting chronic pain patients,
particularly in the first line treatment setting to maximize therapies and response. This project
has great potential for sustainability and improvement in patient knowledge surrounding
medication administration to enhance the first line non-opioid pharmacologic treatment of CNCP
in all outpatient settings. The chronic pain medication focused visits can be supported as a
billable service furthering justifying the ease of implantation for further success in the
management of chronic pain and alternative modalities supporting the Connecticut opioid
education initiative and the 2011 Institute of Medicine (IOM) report.
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